Single-use Bioprocessing Material Market

Executive Summary

Single-use Bioprocessing Material Market was valued at US $14.53 billion in 2021 and is projected to grow at 19.14% CAGR over the forecast period to reach US $41.56 billion by 2027. Single-use Bioprocessing Material Market represented US $4.29 billion opportunity over 2019-2021 and estimated to create US $27.03 billion opportunity in 2027 over 2021.

Single-use Bioprocessing Material from Consainsights analyses the Single-use Bioprocessing Material Market in the Life Sciences industry over the forecast period to 2027.

Single-use Bioprocessing Material research report from Consainsights outlines the detailed strategic analysis, trends, market opportunities, growth prospects, industry and market challenges and sustainable solutions to sustain in the competitive environment.

Single-use Bioprocessing Material segmentation includes Product, End User, Region and Geography.

Based on the Product, the Single-use Bioprocessing Material analysis covers Plastic, Silicone, Other materials.

In Product segment, Plastic segment has highest cagr growth of 16.84%.

Based on the End User, the Single-use Bioprocessing Material analysis covers Biopharmaceutical Manufacturers, Life Science R&D and Academic Institutes, Contract Research Organizations (CROs) & Manufacturers (CMOs).

In End User segment, Biopharmaceutical Manufacturers segment has highest cagr growth of 16.84%.

Based on the Region, the Single-use Bioprocessing Material analysis covers North America, Europe, Asia-Pacific, LAMEA, 3M company, Applikon Biotechnology, Cesco Bioengineering Co. Ltd., Danaher Corporation, Eppendorf AG, General Electric Company, Merck KGaA, PBS Biotech Inc., Sartorius Stedim Biotech S.A., Thermo Fisher Scientific Inc..

In Region segment, North America segment has highest cagr growth of 16.84%.

Based on the region, the Single-use Bioprocessing Material analysis covers North America, Europe, Asia-Pacific, Middle-East & Africa, Latin America.

Key companies operating in the market include and so on. This report covers the detailed analysis of the company profiles such as business segments, product portfolio, key brand insights and growth strategies adopted, company SWOT and Strategy analysis along with the financial analysis and analyst insights on the key companies operating in this market.

Market Overview

Definition & Scope

The base currency considered was the US Dollar (USD). Conversion of other currencies to USD was considered on the basis of the average exchange rate for the respective review-period years. The exchange rate conversion for forecast period was determined according to the base year’s conversion rates.

The base year was identified based on the availability of annual reports and secondary information. The base year considered for this study is 2027.

The review period considered for this study is from 2018-2027. The CAGR is for the forecast period, 2022-2027.

Market size estimations for the forecast years were in real terms. Inflation is not part of the pricing, and the average selling price (ASP) was kept constant throughout the forecast period for each country.

Distribution of primary interviews conducted was based on the regional share of the market and the presence of key players in each region.

As a result of data triangulation through multiple methodologies and approaches, the weighted averages of resulting estimates were considered to be the final values.

Currency, Year & Forecast

The currency used in this report is USD, with the market size indicated in terms of USD million/billion.

For companies reporting their revenues in USD, the revenues were taken from their respective annual reports/SEC filings.

For companies reporting their revenues in other currencies, the average annual currency conversion rates were used for a particular year to convert the value to USD Market Definition.

Product

Introduction

In 2021, Plastic segment has the highest revenue of US $7.89 billion and is expected to grow at CAGR of 16.84% by 2027 Plastic segment has highest cagr growth of 16.84%.

Plastic

Plastic segment was valued at US $5.56 billion in 2019 and is projected to grow at 16.84% CAGR over the forecast period to reach US $22.57 billion by 2027. Plastic segment represented US $2.33 billion opportunity over 2019-2021 and estimated to create US $14.68 billion opportunity in 2027 over 2021.

Silicone

Silicone segment was valued at US $4.02 billion in 2019 and is projected to grow at 16.84% CAGR over the forecast period to reach US $16.33 billion by 2027. Silicone segment represented US $1.69 billion opportunity over 2019-2021 and estimated to create US $10.62 billion opportunity in 2027 over 2021.

Other materials

Other materials segment was valued at US $0.65 billion in 2019 and is projected to grow at 16.84% CAGR over the forecast period to reach US $2.65 billion by 2027. Other materials segment represented US $0.27 billion opportunity over 2019-2021 and estimated to create US $1.73 billion opportunity in 2027 over 2021.

End User

Introduction

In 2021, Biopharmaceutical Manufacturers segment has the highest revenue of US $9.06 billion and is expected to grow at CAGR of 16.84% by 2027 Biopharmaceutical Manufacturers segment has highest cagr growth of 16.84%.

Biopharmaceutical Manufacturers

Biopharmaceutical Manufacturers segment was valued at US $6.39 billion in 2019 and is projected to grow at 16.84% CAGR over the forecast period to reach US $25.92 billion by 2027. Biopharmaceutical Manufacturers segment represented US $2.68 billion opportunity over 2019-2021 and estimated to create US $16.85 billion opportunity in 2027 over 2021.

Life Science R&D and Academic Institutes

Life Science R&D and Academic Institutes segment was valued at US $3.76 billion in 2019 and is projected to grow at 16.84% CAGR over the forecast period to reach US $15.25 billion by 2027. Life Science R&D and Academic Institutes segment represented US $1.58 billion opportunity over 2019-2021 and estimated to create US $9.92 billion opportunity in 2027 over 2021.

Contract Research Organizations (CROs) & Manufacturers (CMOs)

Contract Research Organizations (CROs) & Manufacturers (CMOs) segment was valued at US $0.10 billion in 2019 and is projected to grow at 16.84% CAGR over the forecast period to reach US $0.40 billion by 2027. Contract Research Organizations (CROs) & Manufacturers (CMOs) segment represented US $0.04 billion opportunity over 2019-2021 and estimated to create US $0.26 billion opportunity in 2027 over 2021.

Region

Introduction

In 2021, North America segment has the highest revenue of US $5.55 billion and is expected to grow at CAGR of 16.84% by 2027 North America segment has highest cagr growth of 16.84%.

North America

North America segment was valued at US $3.91 billion in 2019 and is projected to grow at 16.84% CAGR over the forecast period to reach US $15.87 billion by 2027. North America segment represented US $1.64 billion opportunity over 2019-2021 and estimated to create US $10.32 billion opportunity in 2027 over 2021.

Europe

Europe segment was valued at US $2.42 billion in 2019 and is projected to grow at 16.84% CAGR over the forecast period to reach US $9.82 billion by 2027. Europe segment represented US $1.01 billion opportunity over 2019-2021 and estimated to create US $6.39 billion opportunity in 2027 over 2021.

Asia-Pacific

Asia-Pacific segment was valued at US $1.50 billion in 2019 and is projected to grow at 16.84% CAGR over the forecast period to reach US $6.07 billion by 2027. Asia-Pacific segment represented US $0.63 billion opportunity over 2019-2021 and estimated to create US $3.95 billion opportunity in 2027 over 2021.

LAMEA

LAMEA segment was valued at US $0.93 billion in 2019 and is projected to grow at 16.84% CAGR over the forecast period to reach US $3.76 billion by 2027. LAMEA segment represented US $0.39 billion opportunity over 2019-2021 and estimated to create US $2.45 billion opportunity in 2027 over 2021.

3M company

3M company segment was valued at US $0.57 billion in 2019 and is projected to grow at 16.84% CAGR over the forecast period to reach US $2.32 billion by 2027. 3M company segment represented US $0.24 billion opportunity over 2019-2021 and estimated to create US $1.51 billion opportunity in 2027 over 2021.

Applikon Biotechnology

Applikon Biotechnology segment was valued at US $0.35 billion in 2019 and is projected to grow at 16.84% CAGR over the forecast period to reach US $1.43 billion by 2027. Applikon Biotechnology segment represented US $0.15 billion opportunity over 2019-2021 and estimated to create US $0.93 billion opportunity in 2027 over 2021.

Cesco Bioengineering Co. Ltd.

Cesco Bioengineering Co. Ltd. segment was valued at US $0.22 billion in 2019 and is projected to grow at 16.84% CAGR over the forecast period to reach US $0.90 billion by 2027. Cesco Bioengineering Co. Ltd. segment represented US $0.09 billion opportunity over 2019-2021 and estimated to create US $0.59 billion opportunity in 2027 over 2021.

Danaher Corporation

Danaher Corporation segment was valued at US $0.13 billion in 2019 and is projected to grow at 16.84% CAGR over the forecast period to reach US $0.54 billion by 2027. Danaher Corporation segment represented US $0.06 billion opportunity over 2019-2021 and estimated to create US $0.35 billion opportunity in 2027 over 2021.

Eppendorf AG

Eppendorf AG segment was valued at US $0.08 billion in 2019 and is projected to grow at 16.84% CAGR over the forecast period to reach US $0.32 billion by 2027. Eppendorf AG segment represented US $0.03 billion opportunity over 2019-2021 and estimated to create US $0.21 billion opportunity in 2027 over 2021.

General Electric Company

General Electric Company segment was valued at US $0.06 billion in 2019 and is projected to grow at 16.84% CAGR over the forecast period to reach US $0.22 billion by 2027. General Electric Company segment represented US $0.02 billion opportunity over 2019-2021 and estimated to create US $0.15 billion opportunity in 2027 over 2021.

Merck KGaA

Merck KGaA segment was valued at US $0.03 billion in 2019 and is projected to grow at 16.84% CAGR over the forecast period to reach US $0.11 billion by 2027. Merck KGaA segment represented US $0.01 billion opportunity over 2019-2021 and estimated to create US $0.07 billion opportunity in 2027 over 2021.

PBS Biotech Inc.

PBS Biotech Inc. segment was valued at US $0.02 billion in 2019 and is projected to grow at 16.84% CAGR over the forecast period to reach US $0.10 billion by 2027. PBS Biotech Inc. segment represented US $0.01 billion opportunity over 2019-2021 and estimated to create US $0.06 billion opportunity in 2027 over 2021.

Sartorius Stedim Biotech S.A.

Sartorius Stedim Biotech S.A. segment was valued at US $0.02 billion in 2019 and is projected to grow at 16.84% CAGR over the forecast period to reach US $0.07 billion by 2027. Sartorius Stedim Biotech S.A. segment represented US $0.01 billion opportunity over 2019-2021 and estimated to create US $0.05 billion opportunity in 2027 over 2021.

Thermo Fisher Scientific Inc.

Thermo Fisher Scientific Inc. segment was valued at US $0.01 billion in 2019 and is projected to grow at 16.84% CAGR over the forecast period to reach US $0.03 billion by 2027. Thermo Fisher Scientific Inc. segment represented US $0.00 billion opportunity over 2019-2021 and estimated to create US $0.02 billion opportunity in 2027 over 2021.